



Thyroid Hormone Levels in Obese Children and Adolescents with Non-Alcoholic Fatty Liver Disease

Emel Torun¹, İlker Tolga Özgen², Selim Gökçe³, Sinem Aydın⁴, Yaşar Cesur²

¹Bezmialem Vakıf University Medical Faculty, Department of Pediatrics, İstanbul, Turkey

²Bezmialem Vakıf University Medical Faculty, Department of Pediatric Endocrinology and Metabolism, İstanbul, Turkey

³Bezmialem Vakıf University Medical Faculty, Department of Pediatric Gastroenterology, İstanbul, Turkey

⁴Bezmialem Vakıf University Medical Faculty, Department of Radiology, İstanbul, Turkey

Introduction

Obesity is the result of higher dietary energy intake that is higher than the energy requirement. It is a multifactorial medical problem which includes environmental and genetic components (1,2). It is also known that obesity in childhood is related with a high risk of possible metabolic disorders in adulthood (3,4). Non-alcoholic fatty liver disease (NAFLD) is one of these metabolic disorders emphasized in this context because of the possibility of its progressing to chronic liver disease (5,6). NAFLD affects 2.6% to 9.8% of children and adolescents and this ratio increases up to 38% to 77% among obese adults (6,7). NAFLD is a potentially serious and multifactorial condition and is associated with other metabolic disorders such as insulin resistance (IR), hypertension and dyslipidemia (7). Hypothyroidism has also been identified as a factor for the development of NAFLD because of its important role in lipid metabolism (8).

Thyroid hormone levels in childhood obesity reveal a variety of inconsistencies from normal to elevated thyroid stimulating hormone (TSH) levels and normal or elevated free triiodothyronine (fT3) or free thyroxine (fT4) levels (9). In adults, subclinical hypothyroidism was found to be related to NAFLD in a dose-dependent manner (10). The relationships between thyroid hormone levels and NAFLD, IR and other metabolic disorders related to obesity have not been fully explained in children. In this present study, we aimed to investigate the relationship between NAFLD and thyroid functions in obese children and compare the thyroid functions of obese children with NAFLD with obese and non-obese children without NAFLD.

ABSTRACT

Objective: We aimed to determine the association of thyroid functions with the components of metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD) in pediatric obese patients.

Methods: The study included 109 obese children (aged 9-15 years) and a control group of 44 healthy age and gender-matched children of normal weight. NAFLD was diagnosed by conventional ultrasound examination. We assessed the anthropometric data and serum biochemical parameters including lipid profile, alanine aminotransferase (ALT), fasting glucose and insulin levels and thyroid stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) levels. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as a measure of IR.

Results: The mean age and gender distributions in the groups were similar ($p=0.23$). The mean body mass index (BMI) z-scores of obese children with grade 2-3 NAFLD were significantly higher than those of the obese children without hepatic steatosis ($p<0.001$). Mean ALT, triglyceride (TG) and LDL cholesterol increased and HDL-cholesterol significantly decreased as the hepatic steatosis increased ($p<0.05$). HOMA-IR levels in obese subjects with grade 2-3 NAFLD were significantly higher than those in both obese children without NAFLD and grade 1 NAFLD ($p=0.05$ and 0.001 , respectively). In the obese subjects, TSH levels were increased significantly as the degree of steatosis increased ($p=0.04$) but fT3 and fT4 levels were not different. In correlation analysis, TSH was significantly correlated with ALT, BMI SDS and the degree of steatosis.

Conclusions: Obese children demonstrate an increase in TSH levels as the degree of steatosis increased.

Key words: Hepatic steatosis, insulin resistance, thyroid hormones

Conflict of interest: None declared

Received: 20.08.2013

Accepted: 16.12.2013

Address for Correspondence

Emel Torun MD, Bezmialem Vakıf University Medical Faculty, Department of Pediatrics, İstanbul, Turkey

Phone: +90 212 453 17 00 E-mail: dr.emeltorun@gmail.com

© Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing.

Methods

This study included 109 consecutive obese children and a control group of 44 healthy non-obese children. The age of the children ranged from 9 to 15 years. The study participants were recruited from Bezmialem Vakıf University Pediatric Endocrinology and Metabolism Outpatient Clinic between January 2011 and February 2013.

Each participant underwent a detailed physical examination including anthropometric measurements, estimation of degree of obesity, systolic and diastolic blood pressure (SBP and DBP) measurements. Children with syndromic obesity (Prader Willi, Laurence-Moon Biedle syndrome, etc.) were excluded, as were those whose obesity had an endocrine cause such as Cushing's syndrome or hypothyroidism. Those with systemic conditions, including cystic fibrosis and inflammatory bowel disease, hepatitis, drug use, history of parenteral nutrition, cigarette use, alcohol use and family history of hereditary hyperlipidemia and/or premature atherosclerosis were also excluded. In patients with fatty liver, antibodies against hepatotropic viruses, serum ceruloplasmin and α 1 antitrypsin levels, autoantibodies against nuclear smooth muscle and liver-kidney microsomal type-1 antigens were screened to eliminate infectious, metabolic and autoimmune liver pathologies in patients with fatty liver. Estimation of obesity is based on a body mass index (BMI) equal to or greater than the 95th percentile for gender and age, BMI% and BMI standard deviation score (SDS) (11). Standing height was measured to the nearest 0.1 cm with a Harpenden fixed stadiometer. Body weight (kg) was measured on a SECA balance scale to the nearest 0.1 kg, with each subject dressed in light underwear. BMI was calculated by dividing weight by height in meters squared (kg/m^2). BP was measured three separate times after the children had been sitting for 10 min and the second and third measurements were averaged. Children with SBP and/or DBP greater than 95th percentile -adjusted for height, age and sex- were considered to have high BP (12).

All blood analyses were performed on fasting samples in both the study and control groups. Cholesterol, high-density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides (TG) were measured using the homogeneous colorimetric enzyme technique (Roche, Cobas 8000, USA). Serum 25-hydroxyvitamin D [25(OH)D] levels were determined using the electrochemiluminescence enzyme immunoassay method (ECLIA, ADVIA Centaur, DPC Co., USA). Glucose was measured by glucose oxidase technique (Siemens Advia 1800, USA) and insulin levels were analyzed by direct chemiluminescence technique (Siemens Centaur, USA). IR was estimated from fasting plasma measurements using homeostasis model assessment of IR (HOMA-IR) [insulin (mU/L) $\times$ glucose (mmol/L)/22.5] (13). IR criteria were HOMA-IR >2.5 for prepubertal children and HOMA-IR >4.0 for adolescents (14).

In accordance with the criteria proposed by WHO, TG levels lower than 150 mg/dL, LDL-cholesterol levels lower than 130

mg/dL and HDL-cholesterol levels higher than 40 mg/dL were considered to be normal (11).

Conventional hepatic US was performed by a radiologist using a GE Logic 9 (USA) with convex transducers (frequency bandwidth 3.5 MHz). The radiologist was blinded to the clinical and laboratory data and to the risk factors of the subjects. Before US examination, the participants rested quietly in a temperature-controlled dark room for 10-15 minutes. Ultrasonographic steatosis scores were defined as follows: no steatosis (grade 0): normal liver echotexture; mild steatosis (grade 1): slight, diffuse increase in fine parenchymal echoes with normal visualization of the diaphragm and portal vein borders; moderate steatosis (grade 2): moderate, diffuse increase in fine parenchymal echoes with slightly impaired visualization of the diaphragm and portal vein borders; severe steatosis (grade 3): fine echoes with poor or no visualization of the diaphragm and portal vein borders, or posterior portion of the right lobe (15). The children were classified into four groups according to their ultrasonographic steatosis scores as follows: non-obese controls with no steatosis; obese, non-NAFLD; obese, degree 1 NAFLD and the obese, degree 2-3 NAFLD group.

Diagnosis of metabolic syndrome (MS) was based on a modification of the National Cholesterol Education Program's Adult Treatment Panel Criteria (16). Because the body proportions normally change during pubertal development and can vary according to the individual variation and since waist circumference is difficult to interpret in children, BMI was used as an index of obesity according to the previously defined criteria (17). MS was defined as the presence of any three of the following five constituent risks: hypertension (elevated BP as SBP or DBP equal or higher than 95th percentile for age and gender); low HDL cholesterol values (below the 5th percentile for age and gender); hypertriglyceridemia (TG above the 95th percentile for age and gender); obesity (BMI equal or higher than 95th percentile for age and gender); and glucose impairment using pediatric reference standards.

Thyroid hormone levels (fT3, fT4 and TSH) were measured using a direct chemiluminescence technique (ADVIA Centaur XP, USA). The norm values for the respective ranges were between 0.8 -5.4 uIU/ml for TSH, between 4.3-8 pmol/L for fT3 and 10.3-25.7 pmol/L for fT4 (18).

Statistical analysis was performed using PASW Statistics, v.13.0. Median and interquartile ranges were used for the metric variables. Mann-Whitney U was used to calculate the difference between two parameters in the groups; the Kruskal Wallis test was used in the calculation of the difference between two parameters in groups with more than two in the same group and between different groups. The Spearman correlation was used for correlation analysis. Categorical data were evaluated using the chi-square test; $p < 0.05$ was accepted as being statistically significant.

The study was approved by the local ethics committee. Written informed consent was obtained from the parents.

Results

The study included 24 obese children without NAFLD (11 female), 44 obese children with grade 1 NAFLD (20 female), 38 obese children with grade 2-3 NAFLD (21 female) and 44 non-obese healthy control subjects without NAFLD (20 female). The median age and gender distribution in the groups were similar ($p=0.168$ and 0.705 , respectively). The median BMI SDS value in obese children was significantly higher than that in the control group ($p<0.001$). The median BMI SDS value was found to be significantly higher in the obese children with grade 2-3 NAFLD compared with those of both the other obese and non-obese subjects ($p<0.001$) (Table 1).

The HOMA-IR values of children with grade 2-3 NAFLD were significantly higher than those of the control group ($p<0.001$), the obese group without steatosis and the obese group with grade 1 hepatic steatosis ($p<0.05$). Median HOMA-IR significantly

increased as the degree of steatosis increased. Median ALT levels in the obese subjects with grade 2-3 NAFLD were significantly higher than those in the controls and in the obese children without NAFLD or grade 1 NAFLD ($p<0.01$). Median total cholesterol levels were similar in all groups ($p=0.263$). LDL cholesterol and TG levels increased and HDL-cholesterol levels decreased significantly as the grade of the steatosis increased ($p<0.001$, <0.05 and <0.05 , respectively) (Table 2).

TSH levels in the obese children with grade 2-3 steatosis were found to be significantly higher than those in the control group, the obese-without steatosis group and the obese grade 1 steatosis group ($p=0.04$). Mean fT4 and fT3 levels did not differ significantly between the groups ($p=0.38$ and 0.22 , respectively) (Table 3).

Median SBP in group 3 was significantly higher compared with the control group, the obese group without steatosis and the obese group with grade 1 steatosis ($p<0.001$). Median

Table 1. Demographic and anthropometric characteristics of the study and control groups

	(1) Obese, non-NAFLD group (n=24)	(2) Obese, grade 1 NAFLD group (n=47)	(3) Obese, grade 2-3 NAFLD group (n=38)	(4) Non-obese control group (n=44)	p
Age (years), median (IQR)	11.5 (3.2)	12.1 (4.5)	12.2 (3.6)	12.8 (1.7)	0.168
Gender (female), n (%)	11 (45.8)	20 (42.6)	21 (55.3)	20 (45.5)	0.705
BMI SDS median (IQR)	1.97 (0.47)	1.98 (0.39)	2.22(0.37)	0.03 (0.78)	<0.001*
*1, 2, 3 vs 4 Statistical tests: Kruskal-Wallis, Mann-Whitney U, Chi-square NAFLD: non-alcoholic fatty liver disease, BMI SDS: body mass index standard deviation score, IQR: interquartile range, vs: versus					

Table 2. Biochemical characteristics of the study and control group

	(1) Obese, non-NAFLD group (n=24) median (IQR)	(2) Obese, grade 1 NAFLD group (n=46) median (IQR)	(3) Obese, grade 2-3 NAFLD group (n=28) median (IQR)	(4) Non-obese control group (n=44) median (IQR)	p
HOMA-IR	3.24 (1.88)	3.80 (2.59)	4.19 (2.50)	1.9 (0.85)	<0.001* 0.05**
Triglyceride (mg/dL)	83.0 (59.5)	101.0 (41.5)	102.5 (73.0)	64.0 (70.0)	<0.001*
Total cholesterol (mg/dL)	158.0 (23.0)	161.0 (27.0)	160.0 (45.0)	150.0 (33.5)	0.263
LDL cholesterol (mg/dL)	94.5 (44.0)	99.0 (34)	111.0 (25.0)	81.0 (32.0)	<0.05*
HDL cholesterol (mg/dL)	49.0 (17.0)	45.0 (18.0)	44.5 (9.0)	57.0 (32.0)	0.05*
ALT (U/L)	20.0 (29.5)	19.0 (7.5)	29.0 (13.0)	14.0 (5.5)	<0.01* <0.05**
TSH (IU/L)	2.1±0.7	2.6±1.6	4.2±3.9	2.2±1.43	0.04***
fT4 (pmol/L)	12.2±5.1	12.3±4.3	12.9±4.4	13.2±2.3	0.38
fT3 (pmol/L)	5.9±1.1	5.8±1.3	5.7±1.1	5.4±0.9	0.22
*1, 2, 3 vs 4; **1 vs 3; ***1, 2, 4 vs 3 Statistical tests: Kruskal-Wallis, Mann-Whitney U NAFLD: non-alcoholic fatty liver disease, HOMA-IR: homeostatic model assessment of insulin resistance, IQR: interquartile range, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TSH: thyroid stimulating hormone, fT4: free thyroxine, fT3: free triiodothyronine					

Table 3. Clinical and laboratory data of the study and control groups

	(1) Obese, non-NAFLD group (n=23)	(2) Obese, grade 1 NAFLD group (n=43)	(3) Obese, grade 2-3 NAFLD group (n=40)	(4) Non-obese control group (n=43)	p
Metabolic syndrome n, (%)	3 (12.5%)	16 (36.2%)	13 (34.2%)	-	0.098
SBP, (mmHg) median (IQR)	100.0 (0.0)	100.0 (7.0)	110.0 (5.0)	100.0 (12.0)	<0.001*
DBP, (mmHg) median (IQR)	62.0 (20.0)	70.0 (20.0)	70.0 (8.8)	60.0 (8.0)	<0.001**
*1, 2, 4 vs 3, ** 1, 4 vs 2, 3 Statistical tests: Kruskal Wallis, Chi- square NAFLD: non-alcoholic fatty liver disease, SBP: systolic blood pressure, DBP: diastolic blood pressure, IQR: interquartile range					

Table 4. The non-parametric correlation analysis of thyroid stimulating hormone (TSH) levels with anthropometric and biochemical features (Spearman's correlation)

	TSH	
	r	p
Age	-0.038	0.696
BMI SDS	-0.303	0.003
ALT	0.250	0.024
TG	0.196	0.078
Total cholesterol	-0.037	0.760
CRP	0.316	0.163
HOMA-IR	0.138	0.193
HDL cholesterol	-0.150	0.182
LDL cholesterol	-0.090	0.475
SBP	0.163	0.102
DBP	0.006	0.956
MS	0.221	0.022
Steatosis degree	0.342	0.001
BMI SDS: body mass index standard deviation score, ALT: alanine aminotransferase, TG: triglyceride, CRP: C-reactive protein, HOMA-IR: homeostasis model assessment of insulin resistance, HDL: high density lipoprotein, LDL: low density lipoprotein, SBP: systolic blood pressure, DBP: diastolic blood pressure, MS: metabolic syndrome		

DBP measurements also increased significantly as steatosis increased ($p<0.001$). MS was noted in 3 of the 23 children (12.5%) in the obese group without steatosis, in 16 of the 43 children (36.2%) in the obese group with grade 1 steatosis and in 13 of the 40 children (34.2%) in the obese group with grade 2-3 steatosis. The occurrence of MS increased as the grade of steatosis increased but did not reach a statistically significant level ($p=0.098$) (Table 3).

The Spearman correlation of TSH levels with other anthropometric and biochemical parameters showed significant correlation with ALT ($r_s=0.250$, $p=0.024$), BMI SDS ($r_s=-0.303$, $p=0.003$) and the degree of steatosis ($r_s=0.342$, $p=0.001$) (Table 4).

Discussion

The prevalence of obesity in both children and adults is increasing worldwide, as is the prevalence of its complications related to the endocrinological, cardiovascular and gastrointestinal systems. NAFLD is a clinico-histopathological entity associated with obesity and is a potentially serious condition because of the associated liver-related morbidity and its possibility of progressing to cirrhosis (7). The relationship between obesity, obesity-related NAFLD and thyroid functions in childhood is an issue which should be brought to attention.

Thyroid functions in obesity reveal a variety of inconsistencies, from normal ft_3 and ft_4 levels to elevated TSH in 10-23% of obese subjects (19). This entity defined as subclinical hypothyroidism is thought to be related to the resistance to thyroid hormones of peripheral tissues and a decreased negative feedback relationship between TSH and peripheral thyroid hormones (20). Subclinical hypothyroidism is also reported to be related to the relative low level of T4 binding protein in obese children (21). The relationships between NAFLD and IR, hypertension and hyperlipidemia have been fully determined but limited studies have been conducted on the effect of hepatic steatosis on thyroid functions in children.

In adults, the first reports pointing to the association between thyroid functions and liver enzyme activity were conducted by Targher et al (22) and emphasized by Itterman (23). One of the most comprehensive studies was conducted by Chung et al (10) in adults and this study revealed that the prevalence of US-diagnosed NAFLD and abnormal ALT levels increased steadily with increasing grades of hypothyroidism. In studies including subjects with biopsy-proven nonalcoholic steatohepatitis (biopsy-proven NASH), subjects with hypothyroidism were found to be more likely to have NAFLD than those without hypothyroidism, even after eliminating the impact of other metabolic disorders combined with obesity such as diabetes, hypertension, hyperlipidemia (24). In another study, Carulli et al (25) found that euthyroid patients with biopsy-proven NASH had higher TSH levels compared with those with simple steatosis. In the study conducted by Pacifico et al (26) consisting of 402

overweight and obese children with NAFLD, the authors tested the hypothesis that thyroid dysfunction might be associated with an increased risk of NAFLD. The results of this study revealed that elevated TSH concentrations were significantly associated with an increased prevalence of hepatic steatosis and elevated ALT concentrations. High TSH levels were associated with increased odds of having hepatic steatosis, hepatic steatosis with elevated ALT, hypertriglyceridemia, elevated total cholesterol and IR after adjustment for age, gender, pubertal status and BMI SDS (26). In our study we investigated the relationship of all the components of MS with degree of hepatic steatosis as well as thyroid functions. In our study, the median LDL-cholesterol, TG, IR and ALT levels were increased and HDL-cholesterol decreased as the hepatic steatosis degree increased. TSH levels -but not fT3 or fT4- were also elevated with increase in the degree of obesity and steatosis. The increase in the TSH levels was correlated with the grade of obesity, grade of steatosis, ALT levels. Within these parameters, the grade of steatosis displayed the strongest correlation. These findings show that the effect of steatosis on TSH levels is not independent from other factors such as obesity and serum lipid levels. Besides, some other factors that were not evaluated in the present study may have an effect on TSH levels.

The relationship between TSH levels and serum lipid profile in obese children has also been investigated. Results of these studies revealed that patients with hypothyroidism have hyperlipidemia, decreased fatty acid oxidation and decreased hepatic output of TG (27,28). In addition, hypothyroidism was found to be associated with lipid peroxidation, one of the leading candidates for cellular injury in patients with hepatosteatosi (29). In our study, the grade 2-3 NAFLD obese group had significantly higher levels of LDL-cholesterol and TG and lower HDL cholesterol levels compared with the obese- non NAFLD and the lean group. These findings showed that the severity of steatosis was correlated with most of the metabolic dysfunctions such as hyperlipidemia in the severely obese group and with higher TSH levels as well. Studies on the relationship between serum lipid profile and TSH levels have revealed that HDL cholesterol was lower in NAFLD obese children with hypothyroidism compared with NAFLD obese children without hypothyroidism (30). In our study, HDL cholesterol was lower in the grade 2-3 NAFLD obese group compared with the obese non-NAFLD and the lean groups, but the differences did not reach a significant level.

SBP and DBP values were found to be higher in the obese NAFLD group as compared with the non-NAFLD group and the lean group. Increased risk of peripheral vascular resistance, increased arterial stiffness and endothelial dysfunction was reported in obese NAFLD children in previous studies (31). Hypertension has also been reported in some studies with subclinical hypothyroidism (29). In our study, both SBP and DBP increased with increase in degree of obesity and increase in severity of steatosis but no correlation was found between BP and TSH levels.

IR, leading to impaired hepatic glucose production and glucose uptake in muscle is a component of the MS. Recent studies have revealed that subclinical hypothyroidism worsens IR (32). It has been reported that increasing levels of TSH and decreasing levels of fT4 are associated with increased IR (29). In our study, IR increased as the degree of steatosis and obesity increased parallel to increased TSH levels but the relationship between TSH and IR disappeared in correlation analysis.

One of the limitations of the present study is its cross-sectional design which permitted only an examination of association, not causation. In addition, some of the observed differences in IR between the study groups may be attributed to gender (which though statistically insignificant, was not exactly matched) and to differences in pubertal stage (which was not assessed). The diagnosis of NAFLD was based on ultrasound data and the severity of liver disease was not confirmed histologically.

In conclusion, our study shows that TSH levels increased as the grade of the steatosis increased. Hypothyroidism might not commonly lead to NAFLD in obese patients but appears to contribute to the degree of the obesity, grade of the steatosis and to the development of the major components of MS.

References

1. Wabitsch M. Overweight and obesity in European children: definition and diagnostic procedures, risk factors and consequences for later health outcome. *Eur J Pediatr* 2000;159(Suppl 1):8-13.
2. Ibáñez L, Valls C, Ferrer A, Marcos MV, Rodríguez-Hierro F, de Zegher F. Sensitization to insulin induces in obese adolescents with anovulatory hyperandrogenism. *J Clin Endocrinol Metab* 2001;86:3595-3598.
3. Kopelman PG. Obesity as a medical problem. *Nature* 2000;404:635-643.
4. Lee YS. Consequences of childhood obesity. *Ann Acad Med Singapore* 2009;38: 75-77.
5. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut* 2009;58:1538-1544. Epub 2009 Jul 21
6. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem? *J Hepatol* 2007;46:1133-1142. Epub 2007 Mar 26
7. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. *J Pediatr Gastroenterol Nutr* 2006;43:413-427.
8. Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? *J Clin Gastroenterol* 2003;37:340-343.
9. Torun E, Cindemir E, Ozgen IT, Oktem F. Subclinical hypothyroidism in obese children. *Dicle Medical Journal* 2013;40:5-8.
10. Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, Yoon JH, Lee HS. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. *J Hepatol* 2012;57:150-156. Epub 2012 Mar 14
11. Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment and treatment of child and adolescent overweight and obesity: summary report. *Pediatrics* 2007;120(Suppl 4):164-192.

12. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. *Paediatrics* 2004;114(Suppl 2):555-576.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412-419.
14. Valerio G, Licenziati MR, Iannuzzi A, Franzese A, Siani P, Riccardi G, Rubba P. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. *Nutr Metab Cardiovasc Dis* 2006;16:279-284. Epub 2006 Mar 20
15. Kim SH, Lee JM, Kim JH, Kim KG, Han JK, Lee KH, Park SH, Yi NJ, Suh KS, An SK, Kim YJ, Son KR, Lee HS, Choi BI. Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images- initial experience. *Radiology* 2005;234:793-803. Epub 2005 Jan 21
16. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-2497.
17. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL. CDC growth charts: United States. *Adv Data* 2000;314:1-27.
18. Corcoran LM, Eastman CJ, Carter JN, Lazarus L. Circulating thyroid hormone levels in children. *Arch Dis Child* 1977;52:716-720.
19. Reinehr T. Obesity and thyroid function. *Mol Cell Endocrinol* 2010;316(2):165-171. Epub 2009 Jun 18
20. Reinehr T andler W. Thyroid hormones before and after weight loss in obesity. *Arc Dis Child* 2002;87:320-323.
21. Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical Hypothyroidism in Patients with metabolic syndrome. *Endocr J* 2007;54:71-76. Epub 2006 Nov 14
22. Targher G, Montagnana M, Salvagno G, Moghetti P, Zoppini G, Muggeo M, Lippi G. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. *Clin Endocrinol (Oxf)* 2008;68:481-484. Epub 2007 Oct 17
23. Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dörr M, Lerch MM, Meyer zu Schwabedissen HE, Rosskopf D, Völzke H. Inverse association between serum free thyroxine levels and hepatic steatosis: results from the study of health in Pomerania. *Thyroid* 2012;22:568-574. Epub 2012 May 10
24. Pagadala MR, Zein CO, Dasarthy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. *Dig Dis Sci* 2012;57:528-534. Epub 2011 Dec 20
25. Carulli L, Ballestri S, Leonardo A, Lami F, Violi E, Losi L, Bonilauri L, Verrone AM, Odoardi MR, Scaglioni F, Bertolotti M, Loria P. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? *Intern Emerg Med* 2011;8:297-305. Epub 2011 May 11
26. Pacifico L, Bonci E, Ferraro F, Andreoli G, Bascetta S, Chiesa C. Hepatic steatosis and thyroid function tests in overweight and obese children. *Inter J Endocrinol* 2013;2013:381014.
27. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. *Int J Obes Relat Metab Disord* 2000;24(Suppl 2):109-112.
28. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. *Mayo Clin Proc* 1993;68:860-866.
29. Pacifico L, Anania C, Ferraro F, Andreoli GM, Chiesa C. Thyroid function in childhood obesity and metabolic comorbidity. *Clin Chim Acta* 2012;413:396-405. Epub 2011 Nov 27
30. Sert A, Pirgon O, Aypar E, Yilmaz H, Odabas D. Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease. *Pediatr Cardiol* 2013;34:1166-1174. Epub 2013 Jan 24
31. Gokce S, Atbinici Z, Aycan Z, Cinar HG, Zorlu P. The relationship between paediatric non-alcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. *Pediatr Cardiol* 2013;34:308-315. Epub 2012 Aug 9
32. Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppas M, Alevizaki M, Mitrou P, Lambadiari V, Boutati E, Nikzas D, Tountas N, Economopoulos T, Raptis SA, Dimitriadis G. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol* 2009;160:785-790. Epub 2009 Jan 13